Nexentis Technologies Inc. develops and operates an AI and data-driven computational biotech platform. The company is headquartered in Hod HaSharon, Israel.
| Revenue (TTM) | 209,000 |
| Gross Profit (TTM) | 135,000 |
| EBITDA | $-6.99M |
| Operating Margin | 0.00% |
| Return on Equity | -119.60% |
| Return on Assets | -37.60% |
| Revenue/Share (TTM) | $0.36 |
| Book Value | $17.76 |
| Price-to-Book | 0.47 |
| Price-to-Sales (TTM) | 4.32 |
| EV/Revenue | 5.81 |
| EV/EBITDA | 0.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -77.80% |
| Shares Outstanding | $1.45M |
| Float | 426,690 |
| % Insiders | 22.64% |
| % Institutions | 1.11% |
Volatility is currently contracting
MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery initiative with Boltz
Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced the signing of an Addendum to the Loan and Partnership Agreement, together with Solterra Renewable Energy Ltd. (“Solterra”) and the other lenders, for its Melz solar PV project in Germany.
MITOLINE ® -Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets
Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), today reported that it has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins as part of its ongoing efforts to expand and refine its small-molecule discovery capabilities.
Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.
MITOLINE ® -Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development
